Figure 3.
Time to acute myeloid leukemia (AML) progression with death as a competing risk according to: (a) baseline karyotype (one patient had no baseline karyotype available and was excluded from the analysis); (b) red blood cell-transfusion independence (RBC-TI) ⩾8 weeks response and (c) partial or complete cytogenetic response. Symbols indicate censored patients (+) or patients who died without AML (∘). Abbreviation: del(5q), chromosome 5q deletion.